Verrica Pharmaceuticals Shares Outstanding History (VRCA)
Verrica Pharmaceuticals reported 17.2M shares outstanding at the end of fiscal 2025.
View full Verrica Pharmaceuticals company overviewVerrica Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 17.2M | 8.0M | +87.17% |
| 2024 | 2024-12-31 | 9.2M | 4.9M | +116.39% |
| 2023 | 2023-12-31 | 4.2M | 131,950 | +3.21% |
| 2022 | 2022-12-31 | 4.1M | 1.4M | +49.33% |
| 2021 | 2021-12-31 | 2.8M | 207,794 | +8.17% |
| 2020 | 2020-12-31 | 2.5M | −34,521.7 | −1.34% |
| 2019 | 2019-12-31 | 2.6M | 8,157.4 | +0.32% |
| 2018 | 2018-12-31 | 2.6M | 2.2M | +594.82% |
| 2017 | 2017-12-31 | 369,949.9 | — | — |
Verrica Pharmaceuticals quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 17.2M | 16.3M | +1756.26% |
| Q1 2026 | 2026-03-31 | 17.2M | 8.0M | +87.15% |
| Q4 2025 | 2025-12-31 | 17.2M | 8.0M | +87.17% |
| Q3 2025 | 2025-09-30 | 9.5M | 4.9M | +108.11% |
| Q2 2025 | 2025-06-30 | 925,452 | −3.3M | −78.20% |
| Q1 2025 | 2025-03-31 | 9.2M | 4.9M | +116.38% |
| Q4 2024 | 2024-12-31 | 9.2M | 4.9M | +116.39% |
| Q3 2024 | 2024-09-30 | 4.6M | 353,624.2 | +8.41% |
| Q2 2024 | 2024-06-30 | 4.2M | 60,400 | +1.44% |
| Q1 2024 | 2024-03-31 | 4.2M | 56,800 | +1.36% |
| Q4 2023 | 2023-12-31 | 4.2M | 131,950 | +3.21% |
| Q3 2023 | 2023-09-30 | 4.2M | 97,050 | +2.36% |
| Q2 2023 | 2023-06-30 | 4.2M | 1.4M | +51.51% |
| Q1 2023 | 2023-03-31 | 4.2M | 1.4M | +51.51% |
| Q4 2022 | 2022-12-31 | 4.1M | 1.4M | +49.33% |
| Q3 2022 | 2022-09-30 | 4.1M | 1.4M | +49.33% |
| Q2 2022 | 2022-06-30 | 2.8M | 10,947.7 | +0.40% |
| Q1 2022 | 2022-03-31 | 2.8M | 13,347.7 | +0.49% |
| Q4 2021 | 2021-12-31 | 2.8M | 207,794 | +8.17% |
| Q3 2021 | 2021-09-30 | 2.8M | 165,351.1 | +6.39% |
| Q2 2021 | 2021-06-30 | 2.8M | 170,022.7 | +6.59% |
| Q1 2021 | 2021-03-31 | 2.7M | 167,622.7 | +6.49% |
| Q4 2020 | 2020-12-31 | 2.5M | −34,521.7 | −1.34% |
| Q3 2020 | 2020-09-30 | 2.6M | 12,074.5 | +0.47% |
| Q2 2020 | 2020-06-30 | 2.6M | 7,419.6 | +0.29% |
| Q1 2020 | 2020-03-31 | 2.6M | 10,600.8 | +0.41% |
| Q4 2019 | 2019-12-31 | 2.6M | 8,157.4 | +0.32% |
| Q3 2019 | 2019-09-30 | 2.6M | 4,842.6 | +0.19% |
| Q2 2019 | 2019-06-30 | 2.6M | 4,392.6 | +0.17% |
| Q1 2019 | 2019-03-31 | 2.6M | 2.2M | +594.92% |
| Q4 2018 | 2018-12-31 | 2.6M | — | — |
| Q3 2018 | 2018-09-30 | 2.6M | — | — |
| Q2 2018 | 2018-06-30 | 2.6M | — | — |
| Q4 2017 | 2017-12-31 | 369,949.9 | — | — |
Verrica Pharmaceuticals shares outstanding trends
Over the last five reported fiscal years, Verrica Pharmaceuticals's shares outstanding moved from 2.5M to 17.2M, a change of 14.6M. The latest reported quarter, Q2 2026, shows 17.2M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Verrica Pharmaceuticals filings at SEC.gov ↗